A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-
assessor trial
期刊名称： Annals of the Rheumatic Diseases
作者： Josef S Smolen,Frank Behrens,Peter Nash,Soyi Liu Leage,Lingnan Li,Hasan
Tahir,Melinda Gooderham,Eswar Krishnan,Hong Liu-Seifert,Sreekumar G
Pillai,Philip S Helliwellseifert
年份： 2020年
期号： 第1期
关键词： ixekizumab;adalimumab;psoriatic arthritis;head-to-head;clinical trial
摘要：Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve
patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs). Methods Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College of Rheumatology criteria (ACR50) and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI100). Major secondary objectives, also at week 24, were to evaluate whether IXE was: (1)...
内容由中国教育图书进出口有限公司引进

版权声明：本站内容均来自互联网，仅供演示用，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系QQ:729038198，我们将在24小时内删除。